Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Potential role of miR-9 and miR-223 in recurrent ovarian cancer

Open access
Laios, Alexandros, O'Toole, Sharon, Flavin, Richard, Martin, Cara, Kelly, Lynne, Ring, Martina, Finn, Stephen P, Barrett, Ciara, Loda, Massimo, Gleeson, Noreen, D'Arcy, Tom, McGuinness, Eamonn, Sheils, Orla, Sheppard, Brian, O' Leary, John·2008·Molecular Cancer

Abstract

Background: MicroRNAs (miRNAs) are small, noncoding RNAs that negatively regulate gene expression by binding to target mRNAs. miRNAs have not been comprehensively studied in recurrent ovarian cancer, yet an incurable disease. Results: Using real-time RT-PCR, we obtained distinct miRNA expression profiles between primary and recurrent serous papillary ovarian adenocarcinomas (n = 6) in a subset of samples previously used in a transcriptome approach. Expression levels of top dysregulated miRNA genes, miR-223 and miR-9, were examined using TaqMan PCR in independent cohorts of fresh frozen (n = 18) and FFPE serous ovarian tumours (n = 22). Concordance was observed on TaqMan analysis for miR-223 and miR-9 between the training cohort and the independent test cohorts. Target prediction analysis for the above miRNA "recurrent metastatic signature" identified genes previously validated in our transcriptome study. Common biological pathways well characterised in ovarian cancer were shared by miR-9 and miR-223 lists of predicted target genes. We provide strong evidence that miR-9 acts as a putative tumour suppressor gene in recurrent ovarian cancer. Components of the miRNA processing machinery, such as Dicer and Drosha are not responsible for miRNA deregulation in recurrent ovarian cancer, as deluded by TaqMan and immunohistochemistry. Conclusion: We propose a miRNA model for the molecular pathogenesis of recurrent ovarian cancer. Some of the differentially deregulated miRNAs identified correlate with our previous transcriptome findings. Based on integrated transcriptome and miRNA analysis, miR-9 and miR-223 can be of potential importance as biomarkers in recurrent ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-7-35

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 301

Metadata

Authors
Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., Finn, S. P., Barrett, C., Loda, M., Gleeson, N., D'Arcy, T., McGuinness, E., Sheils, O., Sheppard, B., & O' Leary, J.
Venue
Molecular Cancer
Published
2008-04-28
Volume
7
Issue
1
Pages
35-35
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2105312329
Cited by
301
References
4
FWCI
6.37
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. https://app.cochat.ai/papers/10.1186/1476-4598-7-35
The paper
Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., Finn, S. P., Barrett, C., Loda, M., Gleeson, N., D'Arcy, T., McGuinness, E., Sheils, O., Sheppard, B., & O' Leary, J. (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Molecular Cancer. https://doi.org/10.1186/1476-4598-7-35

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.